234 related articles for article (PubMed ID: 25368386)
41. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
42. Unfolded protein response transducer IRE1-mediated signaling independent of XBP1 mRNA splicing is not required for growth and development of medaka fish.
Ishikawa T; Kashima M; Nagano AJ; Ishikawa-Fujiwara T; Kamei Y; Todo T; Mori K
Elife; 2017 Sep; 6():. PubMed ID: 28952924
[TBL] [Abstract][Full Text] [Related]
43. A novel feedback loop regulates the response to endoplasmic reticulum stress via the cooperation of cytoplasmic splicing and mRNA translation.
Majumder M; Huang C; Snider MD; Komar AA; Tanaka J; Kaufman RJ; Krokowski D; Hatzoglou M
Mol Cell Biol; 2012 Mar; 32(5):992-1003. PubMed ID: 22215619
[TBL] [Abstract][Full Text] [Related]
44. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
[TBL] [Abstract][Full Text] [Related]
45. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.
Nakshatri H; Bhat-Nakshatri P; Martin DA; Goulet RJ; Sledge GW
Mol Cell Biol; 1997 Jul; 17(7):3629-39. PubMed ID: 9199297
[TBL] [Abstract][Full Text] [Related]
46. UBC9 regulates the stability of XBP1, a key transcription factor controlling the ER stress response.
Uemura A; Taniguchi M; Matsuo Y; Oku M; Wakabayashi S; Yoshida H
Cell Struct Funct; 2013; 38(1):67-79. PubMed ID: 23470653
[TBL] [Abstract][Full Text] [Related]
47. Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor.
Kurebayashi S; Miyashita Y; Hirose T; Kasayama S; Akira S; Kishimoto T
J Steroid Biochem Mol Biol; 1997 Jan; 60(1-2):11-7. PubMed ID: 9182853
[TBL] [Abstract][Full Text] [Related]
48. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
[TBL] [Abstract][Full Text] [Related]
49. IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.
Ning Y; Riggins RB; Mulla JE; Chung H; Zwart A; Clarke R
Mol Cancer Ther; 2010 May; 9(5):1274-85. PubMed ID: 20457620
[TBL] [Abstract][Full Text] [Related]
50. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance.
Schoenlein PV; Periyasamy-Thandavan S; Samaddar JS; Jackson WH; Barrett JT
Autophagy; 2009 Apr; 5(3):400-3. PubMed ID: 19221464
[TBL] [Abstract][Full Text] [Related]
51. Selective, potent blockade of the IRE1 and ATF6 pathways by 4-phenylbutyric acid analogues.
Zhang H; Nakajima S; Kato H; Gu L; Yoshitomi T; Nagai K; Shinmori H; Kokubo S; Kitamura M
Br J Pharmacol; 2013 Oct; 170(4):822-34. PubMed ID: 23869584
[TBL] [Abstract][Full Text] [Related]
52. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
Johnston SR; Lu B; Dowsett M; Liang X; Kaufmann M; Scott GK; Osborne CK; Benz CC
Cancer Res; 1997 Sep; 57(17):3723-7. PubMed ID: 9288779
[TBL] [Abstract][Full Text] [Related]
53. [Mechanism of acquired antiestrogen resistance and its management in breast cancer].
Iino Y; Maemura M; Morishita Y
Nihon Rinsho; 1997 May; 55(5):1149-54. PubMed ID: 9155167
[TBL] [Abstract][Full Text] [Related]
54. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
56. Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells.
Oida K; Matsuda A; Jung K; Xia Y; Jang H; Amagai Y; Ahn G; Nishikawa S; Ishizaka S; Jensen-Jarolim E; Matsuda H; Tanaka A
Sci Rep; 2014 Feb; 4():4057. PubMed ID: 24531845
[TBL] [Abstract][Full Text] [Related]
57. The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens.
Montano MM; Katzenellenbogen BS
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2581-6. PubMed ID: 9122238
[TBL] [Abstract][Full Text] [Related]
58. Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism.
Roberts CG; Gurisik E; Biden TJ; Sutherland RL; Butt AJ
Mol Cancer Ther; 2007 Oct; 6(10):2777-85. PubMed ID: 17913853
[TBL] [Abstract][Full Text] [Related]
59. Antiestrogens suppress effects of transforming growth factor-β in breast cancer cells via the signaling axis estrogen receptor-α and Y-box Binding Protein-1.
Popp SL; Joffroy C; Stope MB; Buck MB; Fritz P; Knabbe C
Anticancer Res; 2013 Jun; 33(6):2473-80. PubMed ID: 23749898
[TBL] [Abstract][Full Text] [Related]
60. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
